These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1366021)

  • 1. [Challenges and concerns in early-phase clinical trials].
    Gordin A; Scheinin H
    Duodecim; 1992; 108(11):1026-36. PubMed ID: 1366021
    [No Abstract]   [Full Text] [Related]  

  • 2. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
    Chang SM; Reynolds SL; Butowski N; Lamborn KR; Buckner JC; Kaplan RS; Bigner DD
    Neuro Oncol; 2005 Oct; 7(4):425-34. PubMed ID: 16212807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 5. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

  • 7. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 8. Italy launches clinical trial for HIV vaccine.
    Nature; 2008 Jul; 454(7204):564. PubMed ID: 18668075
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 10. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 11. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA.
    Rowley SD
    J Hematother; 1993; 2(3):289-92. PubMed ID: 7921991
    [No Abstract]   [Full Text] [Related]  

  • 14. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
    Glazer A; Hedenmalm K
    Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863
    [No Abstract]   [Full Text] [Related]  

  • 18. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical development of anti-tuberculosis drugs.
    Mitchison DA
    J Antimicrob Chemother; 2006 Sep; 58(3):494-5. PubMed ID: 16840430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development plans for new drug abandoned.
    AIDS Patient Care STDS; 2003 Oct; 17(10):540. PubMed ID: 14608974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.